Skip to main content

Table 1 Characteristics of included studies

From: Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa—a systematic review and meta-analysis

 

Author and publication year

Study design, settings, and year

Sex

Mean age (years)

Matched mean age (years)

HIV status

Hypertension definition criteria used for MetS estimate

MetS definition criteria

HIV+

HIV−

HIV+

HIV−

1

Amusa et al., 2016 [33]

Cross sectional, Nigeria, NS

Both

41 ± 7/40 ± 8 α

41  ±  7

40  ±  8

150

50

Not stated

Other

2

Ayodele et al., 2012 [32]

Cross sectional, Nigeria, NS

Both

39.5–9.3

NA

NA

291

NA

≥ 130/85 and on antihypertensive treatment

IDF, ATP, JIS

3

Berhane et al., 2012 [34]

Cross-sectional, Ethiopia, 2010

Both

18 and above

NA

NA

313

NA

≥140/90 and on antihypertensive treatment

ATP

4

Tesfaye et al., 2014 [42]

Cross sectional, Ethiopia, 2012–13

Both

32.7 ± 9.7 (ART) 32.6 ± 7.8 (naïve)

NA

NA

374

NA

≥ 130/85 and on antihypertensive treatment

IDF, ATP

5

Sobieszczyk et al., 2016 [29]

Cross-sectional, South Africa, 2013

Female

Median 24 years

NA

NA

160

NA

≥ 130/85 and on antihypertensive treatment

ATP

6

Obirikorang et al., 2016 [41]

Cross sectional, Ghana,2013

Both

40.3 ± 0.8

NA

NA

433

NA

≥ 130/85 and on antihypertensive treatment

IDF, ATP, WHO

7

Ngatchou et al., 2013 [40]

Cross sectional, Cameroon, 2009–10

Both

41 ± 12α/39 ± 10

39.0 ± 10.0

41 ± 12

108

96

≥ 140/90 and on antihypertensive treatment

IDF

8

Fourie et al., 2010 [35]

Case control, South Africa, 2005

Both

44 ± 7.81α/44 ± 8.04

44.0 ± 8.04

44.0 ± 7.81

300

300

≥ 130/85 and on antihypertensive treatment

IDF, ATP

9

Muhammad et al., 2013 [45]

Cross sectional, Nigeria, 2009

Both

32.5 ± 7.55

NA

NA

200

NA

≥ 140/90 and on antihypertensive treatment

IDF

10

Mbunkah et al., 2014 [38]

Cross sectional, Cameroon, 2010–11

Both

18–70

41.1 ± 11.2

47.3 ± 13.7

173

50

≥ 130/85 and on antihypertensive treatment

ATP

11

Guehi et al., 2016 [30]

Randomized control trial, Ivory Coast, 2008–14

Both

29–42

NA

NA

755

NA

≥ 140/90 and on antihypertensive treatment

ATP

12

Mashinya et al., 2015 [37]

Cross sectional, South Africa, 2013–14

Both

44.8 ± 11.8

NA

NA

214

NA

≥ 140/90 and on antihypertensive treatment

ATP

13

Guira et al., 2016 [31]

Cross sectional, Burkina Faso, 2011

Both

44.8 + 7.4

NA

NA

300

NA

≥ 130/85 and on antihypertensive treatment

IDF

14

Hirigo et al., 2016 [36]

Cross sectional, Ethiopia, 2013

Both

26.5–38

NA

NA

185

NA

≥ 130/85 and on antihypertensive treatment

IDF, ATP

15

Zannou et al., 2009 [28]

Cohort, Benin, 2004–09

Both

38.0 ± 9.7

NA

NA

79

NA

≥ 130/85 and on antihypertensive treatment

IDF

16

Muyanja et al., 2016 [39]

Cross sectional, Uganda, NS

Both

30–43

NA

NA

250

NA

≥ 140/90 and on antihypertensive treatment

ATP

17

Adébayo et al., 2015 [44]

Cross-sectional, Benin, NS

Both

40,7 ± 9,71

NA

NA

244

NA

≥130/85 and on antihypertensive treatment

Other

18

Sawadogo et al., 2005 [43]

Cross sectional, Burkina Faso, 2011

Both

41.4 ± 8.8

NA

NA

400

NA

≥ 140/90 and on antihypertensive treatment

IDF, ATP

  1. NA not applicable, IDF International Diabetes Federation, ATP Adult Treatment Panel III report of the National Cholesterol Education Program, WHO World Health Organization, α HIV negative